Biocryst Pharmaceuticals (BCRX) Free Cash Flow (2010 - 2026)

Biocryst Pharmaceuticals has reported Free Cash Flow for 17 years, with the latest figure at -$62.4 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 126.77% year-over-year to -$62.4 million; the trailing twelve-month figure through Mar 2026 stood at $311.9 million (up 1266.25% YoY), and the FY2025 full-year result was $346.8 million, up 752.49% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$62.4 million, down from $293.0 million in the prior quarter.
• The five-year high for Free Cash Flow was $293.0 million in Q4 2025, with the low at -$78.2 million in Q1 2022.
• Historically, Free Cash Flow has averaged -$1.6 million across 5 years, with a median of -$20.9 million in 2023.
• Annual changes were most pronounced in 2025 — Free Cash Flow surged 5076.53% — and 2026, when it tumbled 126.77%.
• Biocryst Pharmaceuticals' Free Cash Flow stood at -$24.4 million in 2022, then surged by 70.03% to -$7.3 million in 2023, then advanced by 19.39% to -$5.9 million in 2024, then surged by 5076.53% to $293.0 million in 2025, then slumped by 121.3% to -$62.4 million in 2026.
• The last three Free Cash Flow figures came in at -$62.4 million (Q1 2026), $293.0 million (Q4 2025), and $41.0 million (Q3 2025), per Business Quant data.